Jiugan Bio's Subsidiary and Purui Benchmark Enter Strategic Collaboration in Precision Medicine

Yicai Global APP reported that BSBE (300406.SZ) announced that its holding subsidiary, Fuzhou Maixin Biotech Co., Ltd. ("Maixin"), and Precision Scientific (Beijing) Co., Ltd. ("Precision Scientific") signed the "Framework Agreement between Precision Scientific and Fuzhou Maixin" today.

Both parties will fully leverage their respective strengths in medical R&D fields such as the translation of oncology drugs, deepen cooperation, and jointly promote collaboration with drug development enterprises. They will make full preparations for drugs entering the clinical stage, greatly enhance the success rate of clinical trials for anti-cancer drugs, and provide pharmaceutical companies with a brand-new R&D service model in translational medicine.

The company stated that this collaboration aims to fully leverage the technical reserves and advantages of both parties and their affiliated companies in the field of precision medicine, as well as their leading positions and industry influence within their respective sectors. The partnership will deepen comprehensive cooperation in technologies and applications such as genetic sequencing, testing technology, and immunohistochemistry. It will also accelerate the clinical transformation and application of scientific research achievements. Both parties have agreed to establish a long-term, comprehensive strategic partnership to promote the exploration and innovation of cutting-edge technologies, support the continuous advancement of precision medicine, and achieve mutual support, mutually beneficial cooperation, and a win-win outcome in the field of drug development.